Respiratory Infections News

NEW YORK — In this video filmed at the Infectious Diseases in Children Symposium, John V. Williams, MD, describes multiple interventions in development against respiratory syncytial virus, which is currently surging in the United States.

NEW YORK — In this video, Healio Pediatrics Peer Perspective Board Member C. Buddy Creech, MD, MPH, summarizes the “COVID corner” session at the Infectious Diseases in Children Symposium, including his own talk on outpatient treatment.

NEW YORK — In this video filmed at the Infectious Diseases in Children Symposium, John V. Williams, MD, reacts to updated guidelines published by the AAP in reaction to the RSV surge in children.

NEW YORK — It is hoped that the future of COVID-19 vaccines for children will include simplifying the process of getting shots into their arms, CDC medical officer Sara E. Oliver, MD, MSPH, says in this video.

NEW YORK — In this video, Roberta L. DeBiasi, MD, MS, chief of infectious diseases at Children's National Hospital in Washington, D.C., discusses emerging research in post-acute sequelae of COVID-19 — or long COVID — in children.

The bivalent COVID-19 booster vaccine from Pfizer-BioNTech elicited a stronger response against the BQ.1.1 sublineage than the companies’ original vaccine in people aged 55 years and older, according to new data from the companies.

More than 2 years after the COVID-19 pandemic began, new treatments, vaccines and preventive measures have improved safety and disease outcomes for patients with cancer, according to a speaker at Chemotherapy Foundation Symposium.

The 2023 Medicare Physician Fee Schedule does not reflect the important role infectious disease physicians play in safeguarding public health and is a “serious setback” to the ID workforce, the Infectious Diseases Society of America said.

In children exposed to tuberculosis, chest radiography helped in detecting asymptomatic coprevalent TB and predicting incident TB after baseline, according to a study in American Journal of Respiratory and Critical Care Medicine.

Moderna said Monday that data from a phase 2/3 trial showed that its bivalent COVID-19 booster shot triggers a higher antibody response against SARS-CoV-2 omicron subvariants than its original vaccine.